UBS lowered the firm’s price target on GoodRx (GDRX) to $5.25 from $6 and keeps a Neutral rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
- GoodRx Reports Strong Q1 2025 Results
- Positive Outlook on GoodRx Holdings: Strong Growth Potential and Strategic Positioning Justify Buy Rating
- Hold Rating for GoodRx Holdings Amid Revenue Challenges and Uncertainties
- GoodRx Earnings Call: Mixed Sentiment with Growth and Challenges
- GoodRx price target lowered to $4 from $4.75 at BofA